CAR.70/IL15-transduced CB-NK cells(M.D. Anderson Cancer Center)(CAR.70/IL15-transduced CB-NK cells(M.D. Anderson Cancer Center)) - 药物靶点：CD70 x IL15R_在研适应症：晚期肾细胞癌，间皮瘤，转移性骨肉瘤_专利_临床

概要

基本信息

药物类型

CAR-NK

别名

CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells

靶点

CD70 x IL15R

作用机制

CD70抑制剂(CD70抗原抑制剂)、IL15R激动剂(白细胞介素-15受体激动剂)

治疗领域

肿瘤免疫系统疾病心血管疾病+ [4]

在研适应症

晚期肾细胞癌间皮瘤转移性骨肉瘤+ [3]

非在研适应症-

原研机构

The University of Texas MD Anderson Cancer Center

在研机构

The University of Texas MD Anderson Cancer Center

非在研机构-

最高研发阶段临床1/2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 CAR.70/IL15-transduced CB-NK cells(M.D. Anderson Cancer Center) 相关的临床试验

NCT05703854 / Recruiting临床1/2期IIT

Phase I/II Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma

To find a recommended dose of donated NK cells that can be given with lymphodepleting chemotherapy to patients with advanced renal cell carcinoma, mesothelioma, or osteosarcoma. The effects of this therapy will also be studied.

开始日期2023-03-29

申办/合作机构

The University of Texas MD Anderson Cancer Center

NCT05092451 / Recruiting临床1/2期IIT

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

The goal of this clinical research study is to learn about the safety of giving immune cells called natural killer (NK) cells with chemotherapy to patients with leukemia, lymphoma, or multiple myeloma.
Immune system cells (such as NK cells) are made by the body to attack foreign or cancerous cells. Researchers think that NK cells you receive from a donor may react against cancer cells in your body, which may help to control the disease.

开始日期2022-11-01

申办/合作机构

The University of Texas MD Anderson Cancer Center

100 项与 CAR.70/IL15-transduced CB-NK cells(M.D. Anderson Cancer Center) 相关的临床结果

登录后查看更多信息

100 项与 CAR.70/IL15-transduced CB-NK cells(M.D. Anderson Cancer Center) 相关的转化医学

登录后查看更多信息

100 项与 CAR.70/IL15-transduced CB-NK cells(M.D. Anderson Cancer Center) 相关的专利（医药）

登录后查看更多信息

100 项与 CAR.70/IL15-transduced CB-NK cells(M.D. Anderson Cancer Center) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期肾细胞癌	临床2期	美国	The University of Texas MD Anderson Cancer Center	2023-03-29
间皮瘤	临床2期	美国	The University of Texas MD Anderson Cancer Center	2023-03-29
转移性骨肉瘤	临床2期	美国	The University of Texas MD Anderson Cancer Center	2023-03-29
急性髓性白血病	临床2期	美国	The University of Texas MD Anderson Cancer Center	2022-11-01
多发性骨髓瘤	临床2期	美国	The University of Texas MD Anderson Cancer Center	2022-11-01
骨髓增生异常综合征	临床2期	美国	The University of Texas MD Anderson Cancer Center	2022-11-01